Gossamer Bio, Inc. (GOSS) — SEC Financial Statements & Analysis

Gossamer Bio, Inc. (GOSS) is a pharmaceutical preparations company, incorporated in DE. Gossamer Bio, Inc. trades on Nasdaq as: GOSS. Gossamer Bio, Inc. (GOSS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Gossamer Bio, Inc. carries a market cap of $52.80M, a P/E ratio of -0.42x, a P/B ratio of -0.56x, a P/S ratio of 0.99x, an enterprise value of $47.80M, and an EV/EBITDA multiple of -0.29x. On profitability, it posts an operating margin of -311.70%, a net margin of -235.00%, a Return on Equity (ROE) of 178.72%, a Return on Assets (ROA) of -78.81%, and a Return on Invested Capital (ROIC) of -223.94%. Per share, it reports EPS of $-0.39, diluted EPS of $-0.38, free cash flow per share of $-0.51, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 32.43% year-over-year, net income growth of -9.74% year-over-year, and EPS growth of -35.90% year-over-year. On the balance sheet, it maintains a current ratio of 0.53x, a quick ratio of 0.46x, working capital of $-65.06M, a debt-to-equity ratio of -1.82x, a debt ratio of 2.22, an interest coverage ratio of -15.16x, free cash flow of $-162.63M (TTM), and net debt of $-5.00M. Figures sourced from SEC EDGAR.

Market Cap

$52.80M

P/E TTM

-0.42x

EPS TTM

$-0.39

P/B TTM

-0.56x

ROE TTM

178.72%

ROA TTM

-78.81%

Debt To Equity

-1.82x

Free Cash Flow TTM

$-162.63M

Net Revenue TTM Growth 1Y

32.43%

Data as of 2026-06-30 · Source: SEC EDGAR